# Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

> **NCT01873326** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 92 (actual)

## Conditions studied

- Germ Cell Tumors

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Ifosfamide
- **DRUG:** Cisplatin
- **DRUG:** Mesna
- **DRUG:** Bleomycin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT01873326
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-06
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873326, "Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01873326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*